CD8A and synovial sarcoma: A review of immunohistochemistry-based immune biomarker studies in sarcomas, which included PD-L1, FoxP3, and CD8, suggested a positive association with improved survival in specific histologic subtypes, for example, PD-L1 in alveolar RMS, CD163 in embryonal RMS and CD8 in SS [32].